For the families involved, the results end diagnostic journeys that often stretch on for years without an answer. Developmental delay, frequently accompanied by intellectual disability and autism, affects roughly one to three percent of children worldwide, and its cause remains unknown in about 60 percent of affected cases. Modern sequencing has been steadily shrinking that gap: exome and genome studies show that 40 to 60 percent of individuals with undiagnosed developmental delay, and 30 to 39 percent of autism cases, carry pathogenic de novo variants — mutations that appear in the child but in neither parent. The research team used trio exome sequencing, in which the affected child and both parents are sequenced together, to screen eight individuals recruited through the online matchmaking platform GeneMatcher, with clinicians from multiple countries contributing cases. Each child carried a de novo variant in NPTN and no convincing pathogenic change in any known rare-disease gene. The variants were absent from the gnomAD population database, mapped to the canonical NPTN transcript, and classified under American College of Medical Genetics criteria; the investigation was conducted with informed consent and approval from the ethics committee of the University of Leipzig.

Neuroplastin is hardly a household name, but its résumé is remarkable. The NPTN gene produces two principal isoforms in the human brain: neuroplastin-55, expressed broadly in neural tissue, and neuroplastin-65, which is specific to neurons. Both are type I transmembrane glycoproteins of the immunoglobulin superfamily — rod-like proteins studded with antibody-like domains — and both concentrate at synapses, the contact points where neurons exchange chemical signals. The gene is active early and stays active long: neuroplastin messenger RNA appears at high levels across fetal brain regions between 19 and 24 post-coital weeks and reaches peak abundance in the prefrontal cortex of eighteen-year-old individuals, a region central to planning, self-control and social cognition. Because the two isoforms differ in parts of their sequence, some mutations strike both proteins at once, while others damage only the neuronal version. Their most consequential job, however, has only recently come into focus. Neuroplastin-55 and -65 are obligatory binding partners within the protein complexes of more than 95 percent of the four plasma membrane calcium ATPases, PMCA1 through PMCA4 — meaning that without neuroplastin, these pumps cannot assemble and function properly at the cell surface.

That dependency matters because PMCAs are the neuron’s calcium gatekeepers. They are ATP-fed calcium–proton co-transporters that pump calcium ions with extraordinary speed out of the cell and toward the extracellular space, reinstating resting cytosolic levels after every burst of neural activity and thereby regulating intracellular calcium signaling. Beyond mopping up calcium, PMCA pumps help establish the alkaline microenvironment around the synapse that ionotropic glutamate receptors of the NMDA type require for activation — and NMDA receptors are the molecular switches at the heart of synaptic plasticity, learning and memory. Mutations in the genes encoding PMCA1 through 4, known as ATP2B1 through ATP2B4, have already been linked to developmental delay, autism and other neurodevelopmental disorders, each time with the same cellular signature: diminished pump expression or activity and defective restoration of cytosolic calcium. The connection runs deeper still. The expression, stabilization and activity of the pumps depend strongly on neuroplastin binding, and mice lacking Nptn lose massive amounts of PMCA protein and suffer cognitive impairments along with deficits in social and affective behaviors.

The eight NPTN variants described in the study fall into two mechanistic classes. Four affect both isoforms, disrupting the shared backbone of the protein; four affect only neuroplastin-65, through changes in portions of the protein that the neuronal isoform alone contains. Most striking are two unrelated individuals who independently carry the identical nonsense variant — a premature stop signal that truncates the protein — predicted to cause haploinsufficient production of all neuroplastin isoforms, leaving every relevant cell with effectively half its normal supply. Other children carried frameshift mutations, which scramble the protein’s reading frame, and missense substitutions, which swap single amino acids. The genetic backdrop is equally suggestive. NPTN is frequently deleted or duplicated in patients with 15q24 microdeletion syndrome, a chromosomal disorder associated with developmental delay, and a single-nucleotide polymorphism in the NPTN promoter has been associated with thinner frontal and temporal lobes in the left hemisphere of the brain, correlating with intellectual, verbal and non-verbal abilities in adolescents. Earlier work in mice lacking both copies of Nptn had already demonstrated that normal neuroplastin levels are necessary for multiple cognitive functions.

To test whether reduced gene dosage alone could reproduce the human condition, the researchers studied heterozygous Nptn+/− mice, animals carrying a single functional copy of the gene. These mice produced reduced amounts of both neuroplastin and PMCA, confirming in living brain tissue the biochemical coupling that the human genetics implied. Behavior followed. In the three-chamber social test, the standard assay of rodent sociability, each mouse explored three connected compartments in ten-minute phases: first alone for habituation, then alongside one unfamiliar mouse held in a wire cup, and finally with a second newcomer added to the opposite cup. Typical mice gravitate toward novelty, spending more time with the new arrival. The Nptn+/− mice lost that preference, treating stranger and acquaintance with comparable indifference — an endophenotype analog of the social deficits that characterize autism spectrum disorder, detected through repeated-measures analysis of variance with matched littermate controls.

For the missense variants, the team interrogated protein structure before ever touching a cell. Multiple computational predictors — CADD, REVEL, MutPred2, VEST4 and BayesDel — flagged the substitutions as deleterious. Molecular dynamics simulations, run with the Gromacs package and the OPLS-AA force field in explicit water over 100-nanosecond trajectories at physiological temperature and pressure, revealed structural and thermodynamic abnormalities in the mutant proteins. One variant, P342L, was modeled with the Rosetta suite and docked against human PMCA1 and PMCA2 to examine whether the amino acid change, located within the intermembrane space, might weaken the pump-binding interface; another, W135R, was analyzed at the neuroplastin dimer interface, where the protein pairs with itself. When the mutant genes were expressed in human embryonic kidney cells and measured by quantitative Western blotting, the variant proteins accumulated at lower levels than their wild-type counterpart — evidence that the substitutions destabilize neuroplastin itself, not merely its interactions.

The decisive experiment came in living neurons. The researchers cultured hippocampal neurons from embryonic rats, introduced wild-type or mutant human neuroplastin at days ten to eleven in vitro, and co-expressed genetically encoded calcium indicators — GCaMP5G and jGCaMP7f — fluorescent proteins that brighten instantly whenever cytosolic calcium rises. At days fourteen to sixteen, the neurons were stimulated with brief biphasic electrical pulses delivered through field electrodes, and the resulting calcium transients were captured on high-sensitivity cameras and quantified in Fiji/ImageJ. In neurons expressing wild-type neuroplastin, calcium surged and cleared as expected, pumped back down by working PMCA complexes. In neurons expressing the mutant variants, that regulation failed: statistical comparisons using Mann-Whitney U and Wilcoxon matched-pairs tests confirmed that evoked cytosolic calcium transients were no longer properly controlled. The variants, in other words, did not merely weaken the protein — they dismantled the calcium-control machinery that depends on it.

A final test in fruit flies drove the point home with evolutionary force. The researchers generated transgenic Drosophila carrying human neuroplastin-55 under experimental control, integrated into a defined chromosomal landing site on the second chromosome by PhiC31-mediated transformation. Eliminating the fly’s own neuroplastin ortholog is lethal; supplying the human gene in its wild-type form can stand in for the missing protein, a testament to how deeply conserved this molecule’s function is across hundreds of millions of years of divergent evolution. Yet a missense mutation compromising the PMCA interaction failed to prevent that lethal phenotype. Neuroplastin’s indispensability, the result implies, does not reside in some insect-specific role but in the universal business of calcium management at the cell membrane.

Taken together, the evidence sketches a new disease with unusual internal coherence: a neurodevelopmental disorder marked by intellectual disability and autism that originates either from haploinsufficient NPTN gene dosage or from insufficient functionality of mutant neuroplastin — both routes converging on PMCA hypofunction and calcium dysregulation in central neurons. For clinicians, the study adds NPTN to the short list of genes that merit close scrutiny when exome sequencing returns unexplained results in children with developmental delay, and it delivers the immediate, practical currency of diagnosis: a name, a mechanism and a growing community of families connected through matchmaking platforms. For neuroscientists, it cements calcium handling as one of the convergent pathways in autism biology and elevates neuroplastin from a synaptic curiosity to a lynchpin of neuronal physiology whose loss undermines the pumps, the pH balance and the receptors on which cognition depends. The study, published open access in Genome Medicine as volume 18, article 93, points to next steps that include screening larger undiagnosed cohorts for additional NPTN variants and testing whether boosting calcium pump function can rescue struggling neurons — laboratory questions today, but potentially tomorrow’s therapeutic foothold for children whose brains have been quietly losing their grip on calcium control all along.

Microglia, the brain’s resident immune cells, play a crucial role beyond immune defense: they regulate synaptic pruning and clear cellular debris through phagocytosis, processes indispensable for normal brain development. Dysregulation of microglial activity has been increasingly implicated in neurodevelopmental disorders such as ASD. Yet, the genetic and signaling pathways controlling microglial phagocytic function remain only partially understood. This study sheds light on the role of Mll5, a gene hitherto understudied in the context of microglial physiology, highlighting its critical influence on microglial behavior.

The researchers demonstrated that Mll5 haploinsufficiency severely impairs the phagocytic capacity of microglia measured both in vitro and in vivo. Typically, efficient phagocytosis is vital for removing apoptotic cells and synaptic elements during early brain development. The attenuation of this function in Mll5-deficient microglia could thus derail normal neurodevelopmental processes. The investigation utilized cutting-edge imaging and flow cytometry techniques to quantify the extent of phagocytic deficits, marking a significant advancement in dissecting microglial functional impairment linked to genetics.

At the signaling level, the study identifies a disrupted cascade involving TREM2 (Triggering Receptor Expressed on Myeloid cells 2), SGK3 (Serum/Glucocorticoid Regulated Kinase 3), and GSK3β (Glycogen Synthase Kinase 3 beta). TREM2 is a well-established receptor critical to microglial activation and phagocytosis. The researchers observed that Mll5 haploinsufficiency dysregulates TREM2 signaling, altering downstream kinase activities necessary for maintaining phagocytic function. This dysregulation leads to aberrant phosphorylation patterns on SGK3 and GSK3β, pivotal modulators of cytoskeletal dynamics and cellular metabolism.

Further biochemical analyses revealed that impaired TREM2-SGK3-GSK3β signaling compromises microglial actin remodeling and vesicular trafficking, key cellular processes underpinning engulfment and degradation of targets. The findings suggest that Mll5 exerts epigenetic control over components of this pathway, orchestrating transcriptional programs essential for signaling fidelity. These mechanistic insights illuminate how genetic mutations might cascade into cellular dysfunctions associated with neurodevelopmental conditions.

Crucially, perturbations in this microglial pathway translated to whole-animal behavioral phenotypes. Mice harboring Mll5 haploinsufficiency exhibited behaviors that phenocopy core features of ASD, including social interaction deficits and repetitive behaviors. Behavioral assays such as the three-chamber social test, self-grooming quantifications, and open field explorations confirmed these ASD-like phenotypes. This link between microglial phagocytic dysfunction and neurobehavioral manifestations underscores the pivotal role of immune-brain interactions in neurodevelopmental disorders.

The study also carries profound implications for therapeutic development. By pinpointing the TREM2-SGK3-GSK3β axis as a critical node disrupted by Mll5 deficiency, it opens avenues for targeted pharmacological intervention. Modulators of GSK3β activity, already explored in other neurological contexts, may hold promise for restoring microglial function and ameliorating ASD-like symptoms. Furthermore, enhancing TREM2 signaling through agonists or stabilizers could represent a novel strategy to counteract microglial impairment in genetically susceptible individuals.

An intriguing aspect of the research is the revelation of Mll5 as an epigenetic regulator linking gene expression to functional outcomes in the immune cells of the brain. Mll5 belongs to the mixed-lineage leukemia (MLL) family of histone methyltransferases, although its precise enzymatic functions remain somewhat enigmatic. The authors’ data suggest that Mll5 modulates chromatin landscapes at loci governing microglial receptors and signaling molecules, thus integrating genetic and epigenetic layers to maintain microglial health and neurodevelopmental integrity.

This study underscores the importance of microglia in shaping neural circuits during critical developmental periods and raises the possibility that subtle genetic alterations affecting immune cells can exert outsized effects on brain function and behavior. By incorporating genetic, cellular, molecular, and behavioral analyses in a comprehensive framework, the work defines a new frontier in neuroimmunology research, illustrating the intricate interplay between microglia and neuronal networks.

Technological advances enabled this research, including single-cell transcriptomics and advanced imaging modalities, which allowed the team to dissect cellular heterogeneity and spatial localization of microglial dysfunction in the brain. These tools unraveled how Mll5 haploinsufficiency manifests at the cellular level, providing unprecedented resolution of the molecular pathology that drives altered microglial activity and consequential developmental anomalies.

The translational relevance of this work cannot be overstated. ASD, a complex and heterogeneous disorder, has long eluded conclusive unifying pathogenic models given its multifaceted genetic and environmental contributors. The identification of microglial dysfunction driven by a specific genetic deficit offers a promising biomarker and target for future diagnostics and precision medicine approaches. It also advocates for greater emphasis on the brain’s innate immune system as a critical factor in neurodevelopmental pathophysiology.

Moreover, these findings enrich the growing literature implicating TREM2 beyond Alzheimer’s disease, where it is also known to regulate microglial response and neuroinflammation. The discovery that TREM2-mediated signaling is integral to neurodevelopmental brain function expands its biomedical significance and suggests broader roles for microglial receptors in health and disease across the lifespan.

Future investigations will need to explore the potential reversibility of microglial deficits upon restoration of Mll5 expression or pharmacological modulation of the implicated signaling pathway. Longitudinal studies assessing critical windows for microglial intervention could illuminate when therapeutic strategies might be most effective, offering critical insights for clinical translation.

Furthermore, the work invites deeper examination into how microglia interact with other glial cells and neurons within affected brain regions during development. Understanding these cellular dialogues will be important to fully map the cascade from gene disruption to complex behavioral outcomes. Such integrative approaches could refine our understanding of ASD’s heterogeneity and inform personalized therapeutic designs.

In conclusion, this landmark study by Gao et al. represents a major stride in unraveling the molecular etiology of autism spectrum disorders. By linking Mll5 haploinsufficiency to microglial dysfunction via dysregulated TREM2-SGK3-GSK3β signaling, the research reveals a critical immune-neural interface that shapes neurodevelopment and behavior. Its findings herald a new paradigm emphasizing the microglial contribution to ASD and open exciting prospects for targeted therapies aimed at restoring microglial function and improving outcomes for affected individuals.

Article References:
Gao, S., Lin, Q., Liu, X. et al. Mll5 haploinsufficiency attenuates microglial phagocytosis through dysregulated TREM2-SGK3-GSK3β signaling and recapitulates ASD-like behaviors in mice. Nat Commun (2026). https://doi.org/10.1038/s41467-026-71922-x

Image Credits: AI Generated